FindTrial
Sign In

Changes and Relations of Serum Apelin and TGF-ß1 Levels in Diabetic Nephropathy Patients

Exploring the mechanism of apelin regulating renal tubular epithelial-mesenchymal transition of diabetes through Smad2/3 pathways

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060945
Enrollment
Unknown
Registered
2022-06-14
Start date
2021-02-18
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

the controls :none
Non-DN group:none
DN group:none

Sponsors

The Fifth People’s Hospital of Jinan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
28 Years to 75 Years

Inclusion criteria

Inclusion criteria: Thirty-one patients with diabetic nephropathy (DN group), 39 patients with non-diabetic nephropathy (Non-DN group), and 30 healthy controls were explored. Patients with hyperglycemia were treated with glucose-lowering or lipid-lowering drugs to adjust the FBG below 7.0mmol/L,the postprandial 2 hours plasma glucose(2hPG) below 10.0mmol/L.

Exclusion criteria

Exclusion criteria: All patients were excluded from serious heart, lung, liver and brain diseases, malignant tumor, urinary tract infections and other kidney diseases, recent nephrotoxic drug exposure, and proteinuria caused by other factors.

Design outcomes

Primary

MeasureTime frame
Apelin-13;TGF-ß1;—

Countries

China

Contacts

Public ContactQi Wang
wangq1987.love@163.com18953129050

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026